Search
-
A meta-analysis comparing first-line immunosuppressants in neuromyelitis optica
(Annals of Clinical and Translational Neurology. vol. 8, n° 10, pp. 2025-2037, 2021-10)Article de revueOpen access -
Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab
(Neurology. vol. 8, n° 4, 2021-04-26)Article de revueOpen access -
French validation of the Brief International Cognitive Assessment for Multiple Sclerosis
(Revue Neurologique. vol. 177, n° 1-2, pp. 73-79, 2021-01)Article de revue -
Do isolated cognitive relapses exist? Commentary
(Multiple Sclerosis Journal. vol. 27, n° 10, pp. 1489-1490, 2021-09)Article de revueOpen access -
Validation of the French version of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS)
(Multiple Sclerosis and Related Disorders. vol. 48, 2021-02)Article de revueOpen access -
SMILE: a predictive model for Scoring the severity of relapses in MultIple scLErosis
(Journal of Neurology. vol. 268, n° 2, pp. 669-679, 2021-02)Article de revue -
Insights on the Relationship Between Hippocampal Connectivity and Memory Performances at the Early Stage of Multiple Sclerosis
(Frontiers in Neurology. vol. 12, 2021-05-19)Article de revueOpen access -
Structural constraints of functional connectivity drive cognitive impairment in the early stages of multiple sclerosis
(Multiple Sclerosis Journal. vol. 27, n° 4, pp. 559-567, 2021-04)Article de revue -
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts
(CNS drugs. vol. 35, n° 11, pp. 1217-1232, 2021-11)Article de revue -
Comparison of Simoa™ and Ella™ to assess serum neurofilament-light chain in multiple sclerosis
(Annals of Clinical and Translational Neurology. vol. 8, n° 5, pp. 1141-1150, 2021-05)Article de revueOpen access